Do analysts prefer GTBP or EDSA?

Edesa Biotech has a consensus price target of $5.00, suggesting a potential downside of 11.97%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger valuation and earnings, GTBP or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$6.33 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is GTBP or EDSA more profitable?

GT Biopharma's return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Edesa Biotech N/A -286.52% -75.36%

Do analysts prefer EXOZ or GTBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EXOZ or GTBP more profitable?

GT Biopharma's return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% GT Biopharma N/A N/A -102.03%

Do analysts rate GTBP or IMA?

ImageneBio has a consensus price target of $26.50, suggesting a potential upside of 343.89%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts clearly believe ImageneBio is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImageneBio 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, GTBP or IMA?

ImageneBio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$6.33 N/A ImageneBio N/A N/A -$45.35M -$5.79 N/A

Is GTBP or IMA more profitable?

GT Biopharma's return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% ImageneBio N/A -38.96% -34.60%

Do analysts rate OKYO or GTBP?

OKYO Pharma presently has a consensus price target of $5.67, indicating a potential upside of 272.81%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts plainly believe OKYO Pharma is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, OKYO or GTBP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A GT Biopharma N/A N/A -$28.35M -$6.33 N/A

Is OKYO or GTBP more profitable?

Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A GT Biopharma N/A N/A -102.03%

Do analysts recommend GTBP or IMMP?

Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,314.25%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Prima BioMed is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, GTBP or IMMP?

GT Biopharma has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$6.33 N/A Prima BioMed $6.69M 8.57 -$39.78M N/A N/A

Is GTBP or IMMP more profitable?

Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Prima BioMed N/A N/A N/A

GT Biopharma (GTBP) Competitors

$0.35 -0.01 (-3.54%)

Closing price 04:00 PM Eastern

Extended Trading

$0.34 0.00 (-0.17%)

As of 04:37 PM Eastern

Compare

GTBP vs. EDSA, EXOZ, IMA, OKYO, and IMMP

Should you buy GT Biopharma stock or one of its competitors? MarketBeat compares GT Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GT Biopharma include Edesa Biotech (EDSA), eXoZymes (EXOZ), ImageneBio (IMA), OKYO Pharma (OKYO), and Prima BioMed (IMMP). These companies are all part of the "pharmaceutical products" industry.

How does GT Biopharma compare to Edesa Biotech?

GT Biopharma (NASDAQ:GTBP) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 1.2% of GT Biopharma shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Edesa Biotech has a consensus price target of $5.00, suggesting a potential downside of 11.97%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

GT Biopharma has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

GT Biopharma's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Edesa Biotech	N/A	-286.52%	-75.36%

Edesa Biotech is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

In the previous week, GT Biopharma's average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.

Company	Overall Sentiment
GT Biopharma	Neutral
Edesa Biotech	Neutral

Summary

Edesa Biotech beats GT Biopharma on 9 of the 12 factors compared between the two stocks.

How does GT Biopharma compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

eXoZymes has a beta of 2.73, indicating that its stock price is 173% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

8.2% of GT Biopharma shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 1.2% of GT Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GT Biopharma's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
GT Biopharma	N/A	N/A	-102.03%

In the previous week, eXoZymes' average media sentiment score of 0.00 equaled GT Biopharma'saverage media sentiment score.

Company	Overall Sentiment
eXoZymes	Neutral
GT Biopharma	Neutral

eXoZymes has higher revenue and earnings than GT Biopharma. eXoZymes is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	671.67	-$9.16M	-$1.14	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

Summary

eXoZymes beats GT Biopharma on 5 of the 9 factors compared between the two stocks.

How does GT Biopharma compare to ImageneBio?

GT Biopharma (NASDAQ:GTBP) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

ImageneBio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
ImageneBio	N/A	N/A	-$45.35M	-$5.79	N/A

GT Biopharma has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

In the previous week, GT Biopharma's average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company	Overall Sentiment
GT Biopharma	Neutral
ImageneBio	Neutral

GT Biopharma's return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
ImageneBio	N/A	-38.96%	-34.60%

ImageneBio has a consensus price target of $26.50, suggesting a potential upside of 343.89%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts clearly believe ImageneBio is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 1.2% of GT Biopharma shares are held by company insiders. Comparatively, 2.2% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ImageneBio beats GT Biopharma on 7 of the 11 factors compared between the two stocks.

How does GT Biopharma compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

OKYO Pharma presently has a consensus price target of $5.67, indicating a potential upside of 272.81%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts plainly believe OKYO Pharma is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, OKYO Pharma had 12 more articles in the media than GT Biopharma. MarketBeat recorded 12 mentions for OKYO Pharma and 0 mentions for GT Biopharma. OKYO Pharma's average media sentiment score of 0.34 beat GT Biopharma's score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
OKYO Pharma	Neutral
GT Biopharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
GT Biopharma	N/A	N/A	-102.03%

OKYO Pharma has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 1.2% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

OKYO Pharma beats GT Biopharma on 8 of the 10 factors compared between the two stocks.

How does GT Biopharma compare to Prima BioMed?

GT Biopharma (NASDAQ:GTBP) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,314.25%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Prima BioMed is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, GT Biopharma's average media sentiment score of 0.00 equaled Prima BioMed'saverage media sentiment score.

Company	Overall Sentiment
GT Biopharma	Neutral
Prima BioMed	Neutral

8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 1.2% of GT Biopharma shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GT Biopharma has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Prima BioMed	$6.69M	8.57	-$39.78M	N/A	N/A

GT Biopharma has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Prima BioMed	N/A	N/A	N/A

Summary

Prima BioMed beats GT Biopharma on 7 of the 9 factors compared between the two stocks.

Get GT Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GTBP vs. The Competition

Export

Metric	GT Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.32M	$3.64B	$6.77B	$12.60B
Dividend Yield	N/A	2.18%	2.67%	9.67%
P/E Ratio	-0.05	21.35	26.91	23.97
Price / Sales	N/A	174.30	507.72	91.38
Price / Cash	22.79	150.24	49.71	59.37
Price / Book	1.50	8.00	10.56	6.16
Net Income	-$28.35M	$23.81M	$3.60B	$331.71M
7 Day Performance	-1.37%	-3.23%	-2.15%	-1.94%
1 Month Performance	-29.54%	-0.70%	0.11%	-2.49%
1 Year Performance	-82.63%	41.99%	22.63%	17.28%

GT Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GTBP GT Biopharma	0.1571 of 5 stars	$0.35 -3.5%	N/A	-82.3%	$15.32M	N/A	N/A	8
EDSA Edesa Biotech	1.0159 of 5 stars	$6.74 -1.0%	$5.00 -25.8%	+150.2%	$64.91M	N/A	N/A	20
EXOZ eXoZymes	0.1844 of 5 stars	$7.00 +9.9%	N/A	-43.8%	$64.47M	$70K	N/A	29
IMA ImageneBio	2.0099 of 5 stars	$6.02 -1.5%	$26.50 +340.2%	-60.6%	$64.11M	$800K	N/A	70	Gap Down
OKYO OKYO Pharma	2.8129 of 5 stars	$1.58 +1.9%	$5.67 +258.6%	-48.9%	$64.09M	N/A	N/A	7	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GTBP) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GT Biopharma (GTBP) Competitors

GTBP vs. EDSA, EXOZ, IMA, OKYO, and IMMP

How does GT Biopharma compare to Edesa Biotech?

Summary

How does GT Biopharma compare to eXoZymes?

Summary

How does GT Biopharma compare to ImageneBio?

Summary

How does GT Biopharma compare to OKYO Pharma?

Summary

How does GT Biopharma compare to Prima BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GT Biopharma (GTBP) Competitors

GTBP vs. EDSA, EXOZ, IMA, OKYO, and IMMP

How does GT Biopharma compare to Edesa Biotech?

Do insiders and institutionals believe in GTBP or EDSA?

Do analysts prefer GTBP or EDSA?

Which has more volatility and risk, GTBP or EDSA?

Is GTBP or EDSA more profitable?

Which has stronger valuation and earnings, GTBP or EDSA?

Does the media refer more to GTBP or EDSA?

Summary

How does GT Biopharma compare to eXoZymes?

Do analysts prefer EXOZ or GTBP?

Which has more volatility and risk, EXOZ or GTBP?

Do institutionals and insiders hold more shares of EXOZ or GTBP?

Is EXOZ or GTBP more profitable?

Does the media refer more to EXOZ or GTBP?

Which has better valuation & earnings, EXOZ or GTBP?

Summary

How does GT Biopharma compare to ImageneBio?

Which has stronger valuation & earnings, GTBP or IMA?

Which has more risk & volatility, GTBP or IMA?

Does the media favor GTBP or IMA?

Is GTBP or IMA more profitable?

Do analysts rate GTBP or IMA?

Do institutionals and insiders hold more shares of GTBP or IMA?

Summary

How does GT Biopharma compare to OKYO Pharma?

Do analysts rate OKYO or GTBP?

Does the media favor OKYO or GTBP?

Which has preferable valuation & earnings, OKYO or GTBP?

Is OKYO or GTBP more profitable?

Which has more risk and volatility, OKYO or GTBP?

Do insiders and institutionals believe in OKYO or GTBP?

Summary

How does GT Biopharma compare to Prima BioMed?

Do analysts recommend GTBP or IMMP?

Does the media prefer GTBP or IMMP?

Do institutionals and insiders believe in GTBP or IMMP?

Which has preferable valuation & earnings, GTBP or IMMP?

Which has more risk & volatility, GTBP or IMMP?

Is GTBP or IMMP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools